Dyspnea, commonly known as breathlessness, is a prevalent symptom in various medical conditions. Its etiology is multifactorial, making its clinical management complex.
Understanding the pathophysiology of dyspnea assists in formulating a comprehensive clinical approach. It involves the interplay of peripheral and central mechanisms.
Assessment of dyspnea should include a thorough history, physical examination, and appropriate investigations. It aids in identifying the underlying cause.
Treatment should target the underlying cause. Symptomatic treatment is also essential in managing dyspnea.
Decoding dyspnea requires a comprehensive clinical approach, understanding its pathophysiology, and individualized patient management.
1.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
2.
New drug combination shows particularly good results in patients with HPV-negative head and neck cancer
3.
Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL
4.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
5.
In a clinical trial, "3D mammography" nearly reduces the incidence of breast cancer between two screening exams.
1.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
2.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
3.
Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment
4.
Quality of Life Optimization in Long-Term Cancer Survivorship
5.
Molecular Matching for Individualized Blood-Disorder Therapy
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
5.
How Nutrition Can Support Patients During Cancer Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation